Jan 7 2010
The Cystinosis Research Foundation of
Irvine, Calif., announced it awarded $1.75 million in 11 new grants to
researchers in the United States, Canada, Belgium and Italy who are working
to find a cure for cystinosis, a rare, deadly metabolic and genetic disease
that afflicts about 500 children and young adults in the U.S. and 2,000
worldwide.
"This brings the amount of funded research in 2009 to $3.3 million, the
largest one-year award total ever. With more than $10.8 million in grants
for cystinosis research
issued by the CRF since 2003, our foundation is the leading funding source
for bench and clinical investigations worldwide. Every day, CRF-funded
researchers around the world get closer to unlocking the mysteries of this
terrible disease. We believe we will find a cure in five to 10 years,"
said Nancy Stack, CRF president.
The largest grant in this latest round of funding was $308,602. It was
awarded to Dr. Paul Goodyear, M.D., at the Montreal Children's Hospital in
Quebec and Dr. Francesco Emma, M.D., at the Bambino Gesù Children's
Hospital in Rome for a two-year study on "Stem Cell Microvesicles Rescue
Cystinosis in Vitro."
Eight CRF grants went to researchers on the San Diego and San Francisco
campuses of the University of California and the Scripps Research Institute
in La Jolla, Calif. Researchers in Belgium were awarded grants for two
separate studies.
Cystinosis is a metabolic disease that slowly destroys every organ in the
body, including the liver, kidneys, eyes, muscles, thyroid and brain. There
is a medicine that prolongs the children's lives, but there is no cure.
Almost all sufferers succumb before 40 years old.
In patients with cystinosis, the amino acid cystine accumulates in the
tissue due to the inability of the body to transport cystine out of the
cell. This causes development of crystals, resulting in early cell death.
"The advancements achieved so far are the result of the CRF's focused
efforts and targeted approaches to research. The CRF is funding the best
and brightest scientists at world-renown institutions who are focused on
better treatments and a cure for cystinosis. This strategy has produced a
greater understanding of the disease and the first improved treatment now
in clinical trials in more than 25 years," Stack said.
In the spring 2009 round of funding, $1.6 million in grants were issued to
researchers in the United States and France.
The CRF currently is funding more than 30 research studies, including 10
research fellows worldwide. In 2008, the CRF funded 12 studies with grants
totaling $1,741,889. The CRF also has directed significant funds to
stem-cell and gene-therapy research while supporting researchers whose work
is translatable into new treatments.
The CRF has scheduled its second International Cystinosis Research
Symposium for April 8-9, 2010 at the Arnold and Mabel Beckman Center of the
National Academies of Engineering and Science adjacent to the campus at the
University of California, Irvine, Calif. The first symposium was held in
2008. It facilitated the formation of collaborative relationships among its
research teams. More than 60 cystinosis researchers from the United States
and Europe attended the symposium.
Nancy Stack and her husband, Geoffrey, an owner of the SARES•REGIS Group,
an Irvine real estate company, have a daughter, Natalie, 18, with
cystinosis.
The CRF has raised more than $12 million, all of which is committed for
medical research. All grants are awarded based on evaluations by the CRF's
Scientific Review Board, which is comprised of leading doctors and research
scientists in the field.
The 11 newly funded research studies, totaling $1,754,629 are:
Bruce Barshop, M.D., Ph.D., Principal Investigator
University of California at San Diego
"Improvement of Intracellular Cystine Measurement"
$62,930 -- 1 year study
Bruce Barshop, M.D., Ph.D.
University of California at San Diego
"Tandem Mass Spectrometer Support"
$160,604 -- 1.5 years
Bruce Barshop, M.D., Ph.D., Mentor
Ilya Gertsman, Ph.D., Research Fellow
University of California at San Diego
"Proteomic Based Identification of Cysteinylated Proteins in
Cystinotic Cells"
$124,214 -- 2 year fellowship
Stephanie Cherqui, Ph.D., Principal Investigator
The Scripps Research Institute, La Jolla, California
"Stem Cell and Gene Therapy for Cystinosis"
$163,340 -- 2 year study
Stephanie Cherqui, Ph.D., Mentor
Brian Yeagy, Ph.D., Research Fellow
The Scripps Research Institute, La Jolla, California
"Stem Cell and Gene Therapy for Cystinosis"
$138,485 -- 2 year fellowship
Pierre J. Courtoy, M.D., Ph.D., Principal Investigator
de Duve Institute, Brussels, Belgium
"Lessons from Cystinotic Mice: Vital Imaging of Protein Handling and
Lysosomal Function, Reciprocal Interactions with Regulatory Kinases,
and Regeneration Potential by Transdifferentiation"
$236,000 -- 2 year study
Ranjan Dohil, M.D., Principal Investigator
University of California at San Diego
"A Study to Evaluate Enteric-Coated Cysteamine Therapy in Patients
with Cystinosis"
$27,226 -- 1 year study
Paul Goodyer, M.D., Principal Investigator
Montreal Children's Hospital, Quebec, Canada
Francesco Emma, M.D., Co-Investigator
Bambino Gesù Children's Hospital and Research Institute, Rome, Italy
"Stem Cell Microvesicles Rescue Cystinosis in Vitro"
$308,602 -- 2 year study
Elena Levtchenko, M.D., Ph.D., Principal Investigator
University Hospital Leuven, Belgium
Roos Masereeuw, Ph.D., and Lambertus van den Huevel, Ph.D.,
Co-Investigators
Radboud University, Nijmegen, The Netherlands
"Role of P-glycoprotein Expression and Function in Cystinotic Proximal
Tubular Cells"
$83,999 -- 1 year study
Robert Mak, M.D., Ph.D., Principal Investigator
University of California at San Diego
"Energy Homeostasis and Muscle Wasting in Nephropathic Cystinosis"
$150,000 -- 2 year study
Holger Willenbring, M.D., Ph.D., Principal Investigator
University of California at San Francisco
"Pluripotent Stem Cells as a Source of Immunocompatible Renal Progenitor
Cells for Therapy of Nephropathic Cystinosis"
$138,625 -- 1 year study
SOURCE: Cystinosis Research Foundation